Several studies, using historical controls and subjective observations, have reported an increased incidence of prolonged apnea and bradycardia after DT-P vaccine in preterm infants. This has resulted in delays in vaccine administration to this vulnerable group of infants.
Case reports of severe apnea requiring resuscitation after immunization initiated concerns regarding possible deleterious effects among preterm infants. 5 Numerous studies subsequently reported an increased incidence in apnea and bradycardia after the DTP immunization of these infants. [6] [7] [8] [9] [10] [11] [12] [13] Whereas early reports pertained to the whole-cell pertussis component, [6] [7] [8] [9] more recent studies reported increased apnea and bradycardia with acellular pertussis as well. [10] [11] [12] [13] Only 1 study to date has not reported an increase in apnea and bradycardia in preterm infants after immunization. 14 Unfortunately, previous studies used clinical observations, possibly subject to observer bias, and historical controls. The objective of our study was to examine the relationship between DTaP immunizations and cardiorespiratory episodes while using a randomized, controlled study design and an objective measurement with verification of the frequency and severity of cardiorespiratory events.
METHODS
This randomized, blinded, controlled clinical trial was conducted in 10 NICUs within the United States between September 1, 2000, and September 30, 2004 . Institutional review board approval was obtained for each participating center. The study population consisted of preterm infants, born at a gestational age Ͻ37 weeks, who were 2 months' chronologic age (Ն56 days and Յ60 days) at time of study entry. All infants remained in the NICU for at least 6 days after enrollment. Infants were considered ineligible for participation, in either study group, when they had active infections, were critically ill, or had unstable vital signs. The decision to initiate vaccination, based on clinical stability, was made by the attending neonatologist. Infants who required assisted ventilation or tracheostomy during the study were excluded from participation. Parental/caregiver consent for enrollment was obtained in writing for all infants.
The basic study design is shown in Fig 1. On enrollment into the study, patients were assigned randomly (by random number assignment) into either the DTaP group or the control group. During the initial 2-day period of the study and subsequent to group assignment, both groups were treated similarly (pretreatment phase). On day 3, after completion of the pretreatment phase, the DTaP group was immunized with either Infanrix or Pediatrix (SmithKline Beecham Biologicals, Pittsburgh, PA). The control group was not immunized until the end of day 4 of the study. The heavy vertical lines represent the timing of immunization. The NICU nurse caring for the infant administered a 0.5-mL dose of the vaccine intramuscularly in the anterolateral thigh.
Throughout the 4-day study, apnea and bradycardia were recorded using bedside event-recording capable monitors (Healthdyne Smart Monitor [Respironics, Murrysville, PA]). These detect central apnea using thoracic impedance and bradycardia using both electrocardiography and beat-to-beat heart rate recording. The monitors were set to alarm and record all respiratory pauses of Ն15 seconds and 10-second averaged heart rate declines to Յ80 beats per minute (bpm). The information stored within the monitor was downloaded at the end of the pretreatment phase (end of day 2) and again at the end of the immunization/control phase (end of day 4). Each of the monitor downloads was assigned a nonsequential code number. Downloads were forwarded, in bulk, to 2 analysts (Drs Kelly and Steinschneider) for independent interpretation. In this manner, the analysts were blinded to the download group and phase status.
Standard definitions were applied by using the Monitor Alarm/Event Recordings (Respiration and ECG): Descriptive Terminology manual. 15 Prolonged apnea was defined as a respiratory pause of Ն20 seconds in duration or Ն15 seconds in duration when associated with bradycardia (Յ80 bpm) for at least 5 seconds. Prolonged bradycardia was defined as a heart rate of Ͻ80 bpm that lasted Ն10 seconds. Severe events were defined as a respiratory pause for Ն30 seconds in duration or a bradycardia of Յ60 bpm for at least 10 seconds. Interscorer reliability was determined by calculating the percentage of alarm events agreed on by the 2 analysts. Any discrepancies in event scoring were resolved after discussion by the analysts, and a single event score was agreed on.
A sample size of 100 infants was required in each of the 2 groups to achieve 80% power in detecting significant differences in the occurrence of prolonged apnea and prolonged bradycardia episodes between the DTaP and control groups. A data form was completed for each infant, consisting of biographical data, maternal data, infant medical data, and immunization information. Statistical analyses were performed by using SAS (SAS Institute Inc, Cary, NC) and StatPac (StatPac, Inc, Bloomington, MS). Differences in patient and treatment characteristics between the experimental (DTaP immunization) and control groups were evaluated by using 2 and t tests of significance. Differences in the outcome data were assessed in 2 ways. The occurrence of prolonged events (apnea, bradycardia, or either event) was calculated as the percentage of infants with Ն1 event, and 2 testing compared the experimental and control groups. The average number of prolonged apnea, prolonged bradycardia, or either event was compared by using t tests. In addition, the percentage of infants with Ն1 severe event was compared between the 2 groups by using 2 . Data are presented as mean and 95% confidence interval or as a proportion and 95% confidence interval. Statistical significance is defined as P Յ .05.
RESULTS
A total of 240 preterm infants were enrolled, and 197 infants completed the study. A total of 43 patients dropped out of the study. Six were discharged from the NICU before the study was completed, 9 were taken out of the study by their parents, 7 became medically unstable, and 21 did not complete the study because of equipment problems. The reasons for dropping out were similar for the DTaP and control groups. Six infants were not included in the analysis because of incomplete recordings, resulting in 191 infants with complete data. Infant characteristics are shown in Table 1 . The mean gestational age at birth of infants in the DTaP group was 26.9 weeks (range: 23-33 weeks) and in the control group was 27.0 weeks (range: 24 -36 weeks). The mean birth weight of infants in the DTaP group was 896 g (range: 463-1788 g) and in the control group was 936 g (range: 502-2928 g). No significant differences were seen between the 2 groups with regard to gestational age at birth, birth weight, length, head circumference, gender, and the incidence of multiple gestations.
The medical characteristics of the infants with regard to the incidence of disease states were also similar (Table  1) . Respiratory distress syndrome, chronic lung disease, sepsis, and intraventricular hemorrhage, frequently associated with extreme prematurity, did not differ between the DTaP and control groups. The number of infants being treated for apnea of prematurity also was not significantly different between the 2 groups. Table 2 summarizes the maternal characteristics of the 2 groups. No significant differences between the groups were seen regarding maternal age at delivery; smoking and drug use during pregnancy; and the presence of maternal preeclampsia, eclampsia, and gestational diabetes.
The infant characteristics at the start of event recordings are shown in Table 3 . The mean postconceptional age for the DTaP group was 34.9 weeks and for control subjects was 35.1 weeks. The mean weight at initiation of event recordings for the experimental group was 1775 g and for the control group was 1766 g. The 2 groups were not statistically different at the initiation of the recordings. Table 3 also shows the percentage of infants who had prolonged apnea or prolonged bradycardia in the pretreatment phase. Again, the 2 groups were not significantly different.
Both groups of infants spent a mean of 46.9 hours on the event-recording monitors during the treatment phase of the study. Interobserver reliability in the interpretation of the event recordings was high and not significantly different between the groups (96.5% for the DTaP group and 98.2% for the control group). Table 4 summarizes the percentage of infants who had Ն1 event of prolonged apnea, prolonged bradycardia, or either prolonged apnea or prolonged bradycardia. Prolonged apnea was seen in 16.1% of infants who received DTaP and 20.4% of control subjects (P Ͼ .05). Among infants in the DTaP group, 58.1% had prolonged bradycardia, whereas 56.1% of control subjects had prolonged bradycardia (P Ͼ .05). Prolonged bradycardia was a much more frequent event than prolonged apnea in our population, with no significant difference in occurrence between the DTaP and control groups. There was also no significant difference in the percentage of infants who had either prolonged apnea or prolonged bradycardia. In the DTaP group, 59.1% had either event, compared with 58.2% in the control group.
Severe events are also summarized in Table 4 . Whereas severe apnea occurred infrequently (3%), severe bradycardia was found in ϳ50% of study infants. Again, there was no difference in the DTaP group versus the control group in either severe apnea (2.2% and 5.1%, respectively) or severe bradycardia (54.8% and 50.0%, respectively).
The study design permitted using the intervention group as its own control. We found no differences when we compared the outcomes in the intervention group for the 48 hours before vaccine administration with the 48 hours after vaccination. The percentage of infants who had prolonged apnea before immunization was 20.4% versus 19.1% after immunization (P Ͼ .05), whereas the percentage was 53.2% before immunization versus 55.9% after immunization for prolonged bradycardia (P Ͼ .05).
DISCUSSION
This prospective, randomized, multicenter study found that extremely preterm infants who received DTaP at 2 months of chronological age were no more likely to experience prolonged episodes of apnea and bradycardia than were randomly assigned control subjects who were not immunized during the study period. This study, conducted in 10 NICUs in the United States during a 4-year period, involved a group of infants who were at increased risk for significant cardiorespiratory events. The study population clearly represented an extremely vulnerable group of infants, as indicated by their gestational age, birth weight, and the high incidence of the common complications of marked prematurity (respiratory distress syndrome, chronic lung disease, sepsis, and intraventricular hemorrhage). The vulnerability of the study population is also demonstrated by the high incidence of both prolonged apnea and prolonged bradycardia, as well as the high incidence of severe cardiorespiratory events: more than half of all infants experienced heart declines to Ͻ60 bpm for at least 10 seconds. Nonetheless, after blinded analysis of more than 3200 hours of event recordings by 2 reviewers with a high degree of interobserver reliability, no differences in cardiorespiratory events were found between these medically fragile infants who received DTaP and those who did not.
The AAP recommends the immunization of preterm infants with the DTaP vaccine at 2 months of chronologic age, regardless of birth weight and gestational age. 1 This recommendation has remained consistent since 1982; however, several investigators have reported that primary care providers often do not adhere to the AAP guidelines. Magoon et al 2 reported immunization delays in 30% to 77% of infants, with the timing of delays ranging from 6 to 40 weeks. They found that the less the birth weight and gestational age, the greater the probability of delay. Langkamp et al 3 reported that very low birth weight infants (Ͻ 1500 g) were less likely to be up-to-date for all immunizations at ages 12, 24, and 36 months compared with infants with higher birth weights. DTaP immunizations have also been administered to preterm infants in reduced dosages that are ineffective. 2, 4 Slack and Shapira 5 published case reports of 4 preterm infants who developed severe apneas that required resuscitation after immunizations. Many studies using historical controls subsequently supported an association between DTP immunization in preterm infants and prolonged apnea and bradycardia. [6] [7] [8] [9] [10] [11] [12] Although earlier studies 6-9 used the whole-cell component of the pertussis vaccine, more recent studies reported increased apnea and bradycardia with acellular pertussis as well. [10] [11] [12] [13] Sanchez et al 8 published the first prospective study of the incidence of apnea and bradycardia after DTP immunization in 1997. No control group was used. They found that 30% of the infants had significant post-DTP events. They advocated the need to monitor closely very preterm infants after DTP immunization, a recommendation echoed by other groups of investigators who reported significant apnea and bradycardia. 8, 9 Pfister et al 10 were the first to report mostly benign, although frequent, cardiorespiratory events after DTaP; however, they relied on historical controls and clinical observa- 14 This study consisted of a retrospective chart review, and no control group was present. Lee et al 13 published a study on the frequency of cardiorespiratory events after immunizations in hospitalized preterm infants using a control group. They reported an increased incidence in adverse events, based on subjective clinical assessments by nurses and the nonsystematic routine use of standard NICU monitors, without any recording of events. The major strengths of the current study are (1) the use of a randomized simultaneous control study design, which allowed for the control of known and unknown confounders; (2) the use of bedside event-recording monitors to assess objectively the frequency, duration, and severity of cardiorespiratory events; and (3) scoring of each monitor event recording by 2 independent analysts who interpreted the recordings blinded to the group or study phase status of the patients.
Our study is the first randomized, blinded, controlled clinical trial to use physiologic recordings of events to compare the incidence of prolonged apnea and prolonged bradycardia in preterm infants who had DTaP immunization versus those who did not. This represents a major advantage over all previous studies in permitting objective assessments of the frequency, duration, and severity of these events after DTaP vaccination, compared with a prospectively randomized control group.
Our study was powered to detect significant differences in the occurrence of either prolonged apnea or prolonged bradycardia between the DTaP and control groups. The available sample size permitted the detection of at least an 89% increase in the proportion of infants with prolonged apnea and at least a 35% increase in the proportion of infants with prolonged bradycardia.
The study design required the continuous use of event recording equipment on preterm infants in NICUs for an extended period of time. Unfortunately, this resulted in a high dropout rate (18%), mostly as a result of technical difficulties involving the equipment. All infants were similar in gestational age and chronologic age. Both the number of dropouts and the reason for dropping out were similar for the DTaP and control groups, so we do not suspect that the results were subject to bias. Nonetheless, we acknowledge the high dropout rate as a limitation of our study.
Because this clinical trial was conducted with preterm infants who remained hospitalized at 2 months of age, these results cannot be generalized to preterm infants in general. Another limitation is that there was no follow-up after NICU discharge and no long-term observation of an untreated control group. It is therefore unclear to what extent these event recordings correlate with risk for later clinically significant events.
CONCLUSIONS
Our results support and validate the long-standing AAP recommendations for immunization of preterm infants at 2 months of chronological age. On the basis of these cardiorespiratory event recordings, clinicians should be reassured that there is no apparent rationale for unnecessary delays in the administration of DTaP immunizations even to very preterm infants.
